Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial

Author:

Ji Linong¹^ORCID,Li Ling²,Kuang Jian³,Yang Tao⁴,Kim Dong-Jun⁵,Kadir Azidah A.⁶,Huang Chien-Ning⁷,Lee Douglas⁸

Affiliation:

1. Department of Endocrinology; Peking University People's Hospital; Beijing China

2. Department of Endocrinology; Shengjing Hospital of China Medical University; Shenyang China

3. Department of Endocrinology; Guangdong General Hospital, Guangdong Academy of Medical Sciences; Guangzhou China

4. Department of Endocrinology; Jiangsu Province Hospital; Nanjing China

5. Department of Internal Medicine; Ilsan Paik Hospital, Inje University; Goyang Korea

6. Department of Family Medicine; Universiti Sains Malaysia; Kubang Kerian Malaysia

7. Department of Endocrinology and Metabolism; Chung Shang Medical University Hospital; Taichung City Taiwan China

8. Takeda Development Centre Europe, Ltd; London United Kingdom

Funder

Takeda Pharmaceutical Company Limited

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference17 articles.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献